GlobeNewswire·Dec 15, 2025, 7:00 AM ET

Jade Biosciences Announces $45 Million Private Placement

Jade Biosciences, Inc. (NASDAQ: JBIO) entered a securities purchase agreement with BB Biotech for a private placement expected to yield approximately $45 million in gross proceeds.
The Company is selling 3,214,286 shares of common stock at $14.00 per share.
The private placement is scheduled to close on or about December 16, 2025, subject to customary closing conditions.
Net proceeds will fund research and development, general corporate expenses, and working capital needs.
Jade will file a registration statement with the SEC to register the resale of shares sold in this unregistered private placement.
Jade's lead candidate JADE101 targets APRIL and is in a Phase 1 trial for immunoglobulin A nephropathy.
The pipeline includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE-003, an undisclosed antibody program, both in preclinical development.